Cyberonics, Inc.  

(Public, NASDAQ:CYBX)   Watch this stock  
Find more results for CYBX
68.50
+1.90 (2.85%)
Feb 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 67.50 - 70.37
52 week 48.19 - 76.48
Open 68.10
Vol / Avg. 1.72M/588,173.00
Mkt cap 1.75B
P/E 29.34
Div/yield     -
EPS 2.34
Shares 26.31M
Beta 0.59
Inst. own 109%
Feb 26, 2015
Q3 2015 Cyberonics Inc Earnings Release
Feb 26, 2015
Q3 2015 Cyberonics Inc Earnings Results and Cyberonics Inc and Sorin SpA M&A Conference Call - Webcast
Jan 14, 2015
Cyberonics Inc at JPMorgan Healthcare Conference
Dec 3, 2014
Cyberonics Inc at Piper Jaffray Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Oct '14) 2014
Net profit margin 23.53% 19.46%
Operating margin 35.77% 28.37%
EBITD margin - 33.00%
Return on average assets 23.62% 19.67%
Return on average equity 25.94% 22.47%
Employees 639 -
CDP Score - -

Address

100 Cyberonics Blvd
HOUSTON, TX 77058-2069
United States - Map
+1-281-2287200 (Phone)
+1-302-6745266 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cyberonics, Inc. is a medical device company, engaged in the design, development, sale and marketing of an implantable medical device, the VNS Therapy System, that delivers a therapy, vagus nerve stimulation (VNS) therapy using pulsed electrical signals applied to the vagus nerve for the treatment of refractory epilepsy and treatment-resistant depression (TRD). The Company is also investigating the use of vagus nerve stimulation and other neuromodulation therapy for other indications, including chronic heart failure, and developing non-implantable device solutions for the management of epilepsy. As of April 25, 2014, the Company had 639 employees globally. The applications of VNS Therapy system are into Epilepsy, Depression, and treatment for Chronic Heart Failure.

Officers and directors

Daniel Jeffrey Moore President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Gregory H. Browne Chief Financial Officer, Senior Vice President - Finance
Age: 61
Bio & Compensation  - Reuters
Rohan H. Hoare Ph.D. Chief Operating Officer, Senior Vice President
Age: 49
Bio & Compensation  - Reuters
David S. Wise Senior Vice President, Chief Administrative Officer, Secretary
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Randal L. Simpson Vice President - Operations
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Darren W. Alch Vice President, General Counsel, Assistant Secretary
Age: 48
Bio & Compensation  - Reuters
Mark S. Verratti Vice President - Global Sales
Age: 46
Bio & Compensation  - Reuters
Bruce H. KenKnight Ph.D. Vice President - Emerging Therapy
Age: 53
Bio & Compensation  - Reuters
Bryan D. Olin Ph.D. Vice President - Clinical , Quality & Regulatory
Age: 47
Bio & Compensation  - Reuters
Sherrie L. Perkins Vice President - Marketing & New Business Development
Age: 60
Bio & Compensation  - Reuters